Cargando…

Truly continuous low pH viral inactivation for biopharmaceutical process integration

Continuous virus inactivation (VI) has received little attention in the efforts to realize fully continuous biomanufacturing in the future. Implementation of continuous VI must assure a specific minimum incubation time, typically 60 min. To guarantee the minimum incubation time, we implemented a pac...

Descripción completa

Detalles Bibliográficos
Autores principales: Martins, Duarte L., Sencar, Jure, Hammerschmidt, Nikolaus, Flicker, Andreas, Kindermann, Johanna, Kreil, Thomas R., Jungbauer, Alois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187162/
https://www.ncbi.nlm.nih.gov/pubmed/32017010
http://dx.doi.org/10.1002/bit.27292
_version_ 1783527115017158656
author Martins, Duarte L.
Sencar, Jure
Hammerschmidt, Nikolaus
Flicker, Andreas
Kindermann, Johanna
Kreil, Thomas R.
Jungbauer, Alois
author_facet Martins, Duarte L.
Sencar, Jure
Hammerschmidt, Nikolaus
Flicker, Andreas
Kindermann, Johanna
Kreil, Thomas R.
Jungbauer, Alois
author_sort Martins, Duarte L.
collection PubMed
description Continuous virus inactivation (VI) has received little attention in the efforts to realize fully continuous biomanufacturing in the future. Implementation of continuous VI must assure a specific minimum incubation time, typically 60 min. To guarantee the minimum incubation time, we implemented a packed bed continuous viral inactivation reactor (CVIR) with narrow residence time distribution (RTD) for low pH incubation. We show that the RTD does not broaden significantly over a wide range of linear flow velocities—which highlights the flexibility and robustness of the design. Prolonged exposure to acidic pH has no impact on bed stability, assuring constant RTD throughout long term operation. The suitability of the packed bed CVIR for low pH inactivation is shown with two industry‐standard model viruses, that is xenotropic murine leukemia virus and pseudorabies virus. Controls at neutral pH showed no system‐induced VI. At low pH, significant VI is observed, even after only 15 min. Based on the low pH inactivation kinetics, the continuous process is equivalent to traditional batch operation. This study establishes a concept for continuous low pH inactivation and, together with previous reports, highlights the versatility of the packed bed reactor for continuous VI, regardless of the inactivation method.
format Online
Article
Text
id pubmed-7187162
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71871622020-04-28 Truly continuous low pH viral inactivation for biopharmaceutical process integration Martins, Duarte L. Sencar, Jure Hammerschmidt, Nikolaus Flicker, Andreas Kindermann, Johanna Kreil, Thomas R. Jungbauer, Alois Biotechnol Bioeng ARTICLES Continuous virus inactivation (VI) has received little attention in the efforts to realize fully continuous biomanufacturing in the future. Implementation of continuous VI must assure a specific minimum incubation time, typically 60 min. To guarantee the minimum incubation time, we implemented a packed bed continuous viral inactivation reactor (CVIR) with narrow residence time distribution (RTD) for low pH incubation. We show that the RTD does not broaden significantly over a wide range of linear flow velocities—which highlights the flexibility and robustness of the design. Prolonged exposure to acidic pH has no impact on bed stability, assuring constant RTD throughout long term operation. The suitability of the packed bed CVIR for low pH inactivation is shown with two industry‐standard model viruses, that is xenotropic murine leukemia virus and pseudorabies virus. Controls at neutral pH showed no system‐induced VI. At low pH, significant VI is observed, even after only 15 min. Based on the low pH inactivation kinetics, the continuous process is equivalent to traditional batch operation. This study establishes a concept for continuous low pH inactivation and, together with previous reports, highlights the versatility of the packed bed reactor for continuous VI, regardless of the inactivation method. John Wiley and Sons Inc. 2020-02-24 2020-05 /pmc/articles/PMC7187162/ /pubmed/32017010 http://dx.doi.org/10.1002/bit.27292 Text en © 2020 The Authors. Biotechnology and Bioengineering Published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle ARTICLES
Martins, Duarte L.
Sencar, Jure
Hammerschmidt, Nikolaus
Flicker, Andreas
Kindermann, Johanna
Kreil, Thomas R.
Jungbauer, Alois
Truly continuous low pH viral inactivation for biopharmaceutical process integration
title Truly continuous low pH viral inactivation for biopharmaceutical process integration
title_full Truly continuous low pH viral inactivation for biopharmaceutical process integration
title_fullStr Truly continuous low pH viral inactivation for biopharmaceutical process integration
title_full_unstemmed Truly continuous low pH viral inactivation for biopharmaceutical process integration
title_short Truly continuous low pH viral inactivation for biopharmaceutical process integration
title_sort truly continuous low ph viral inactivation for biopharmaceutical process integration
topic ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187162/
https://www.ncbi.nlm.nih.gov/pubmed/32017010
http://dx.doi.org/10.1002/bit.27292
work_keys_str_mv AT martinsduartel trulycontinuouslowphviralinactivationforbiopharmaceuticalprocessintegration
AT sencarjure trulycontinuouslowphviralinactivationforbiopharmaceuticalprocessintegration
AT hammerschmidtnikolaus trulycontinuouslowphviralinactivationforbiopharmaceuticalprocessintegration
AT flickerandreas trulycontinuouslowphviralinactivationforbiopharmaceuticalprocessintegration
AT kindermannjohanna trulycontinuouslowphviralinactivationforbiopharmaceuticalprocessintegration
AT kreilthomasr trulycontinuouslowphviralinactivationforbiopharmaceuticalprocessintegration
AT jungbaueralois trulycontinuouslowphviralinactivationforbiopharmaceuticalprocessintegration